According to Cancer Research UK, cancer survival is improving, and has doubled in the last 40 years in the UK. Intensive research and discoveries allow scientists to develop new and more efficient methodologies to treat cancer.
Although the efficiency of immunotherapy for cancer treatment has been acknowledged throughout the medical history, last couple of decades have witnessed a significant boost thanks to novel biomedical technologies. No need to mention, Cambridge is one of the leading centres of such developments.
Join us for an evening of talks both from academia and the industry on the next generation of immuno-oncology, followed by a panel discussion and networking session with the speakers.
Food and drinks are provided during the networking session.
Talk and Panel discussion
Robert Wilkinson is Director of Oncology Research at MedImmune, the biologics arm of AstraZeneca. Based in Cambridge, his group is charged with the generation and delivery of new candidate biotherapeutics. His research focuses on immunotherapies, as well as tumour targeted therapies using the latest antibody and protein based strategies. Robert has over fifteen years of experience in the biotech and pharmaceutical industries, in both small and large molecule cancer drug discovery, and translational science. Previously he has held senior leadership roles with AstraZeneca and Cancer Research Technology and has a strong track record in progressing pipeline projects and harnessing novel scientific approaches, technologies and directing multidisciplinary teams. Robert received his PhD in Experimental Immunology from The University of Birmingham and has co-authored over 50 publications in the field of immunology and cancer.
Mihriban has over 10 years’ experience in antibody engineering and discovery and has successfully managed a number of collaborative drug discovery projects with big pharma. Prior to joining F-star, she worked in technology enhancement in Biopharm R&D at GlaxoSmithKline (GSK) and in the selection and optimisation of lead domain antibodies (dAbs) at Domantis Ltd. Mihriban holds a PhD in Biochemistry from University of Sussex, UK, and a BSc in Biology from Middle East Technical University, Turkey.
Stephan holds a PhD in molecular biology from the University of Copenhagen and has an MBA from the Copenhagen Business School. As a scientist Stephan has been a co-author in several peer reviewed articles within immunology. In 2014, Stephan became an entrepreneur by co-founding and becoming the CEO of Immunitrack. Immunitrack has key capabilities within in vitro studies of Major Histocompatibility Complex class I and class II (MHCI&II). MHCs are central to the specificity of the adaptive immune system (T cell and B cell). Immunitrack has successfully engaged with 5 of the top 10 pharma companies and world leading research groups focused on immuno-oncology.
Thursday, October 26th 2017
18:00 – 21:00 (GMT)
Department of Chemistry